Latest filing published 20 Nov 2020 for GenMark Diagnostics, Inc., €7,669. Read the official filing
This profile gathers the share dealings of Sarah Hollis Winkler in GenMark Diagnostics, Inc. In total, 14 filings cover trades dated from 30 October 2019 to 19 November 2020.
No open-market purchase appears, only 11 sales worth €115k. Besides market trades, the filings include 2 share grants and 1 option exercise. In 2020 alone, the filings show no purchases and 9 sales.
On 20 November 2020 came the latest disclosure, an open-market sale for €7,669 in GenMark Diagnostics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
14 of 14 declarations